Vaccine News and Research

Latest Vaccine News and Research

New machine-learning program accurately identifies COVID-19 conspiracy theories on social media

A new machine-learning program accurately identifies COVID-19-related conspiracy theories on social media and models how they evolved over time--a tool that could someday help public health officials combat misinformation online.

20 Apr 2021

Despite global efforts, allocation and distribution of COVID-19 vaccines are not equitable

Ensuring COVID-19 vaccine access for refugee and displaced populations, and addressing health inequities, is vital for an effective pandemic response.

20 Apr 2021

Updated insights for safe COVID-19 vaccination in patients with reported allergic reactions

At the end of 2020, experts led by allergists at Massachusetts General Hospital examined all information related to possible allergic reactions to COVID-19 vaccinations.

19 Apr 2021

Sinovac COVID-19 vaccine shows 50% effectiveness in a cohort of Brazilian healthcare workers

CoronaVac is a well-tolerated vaccine containing inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and it induced humoral responses in phase 1 and 2 studies. Analysis of a Brazilian phase 3 clinical trial that evaluated 12,607 participants showed that the vaccine had an efficacy of 50.39% 15 days after the 2nd dose.

19 Apr 2021

Study identifies COVID-19 vaccine inequity in Massachusetts

A new study led by Bisola O. Ojikutu of Brigham and Women’s Hospital in Boston suggests not only do these communities have a higher infection, but they are also experiencing lower vaccine distribution. The team suggests that reformation for equitable vaccine delivery is necessary to eliminate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Apr 2021

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

A small study, previously posted to the medRiv preprint server in early March, was recently published in the journal Science Immunology. The now peer-reviewed research led by E. John Wherry of the University of Pennsylvania Perelman School of Medicine finds people previously exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced a more robust immune response after receiving the first — but not the second mRNA vaccine.

19 Apr 2021

Majority of Americans support COVID-19 vaccine mandates, study finds

As vaccines that help protect against COVID-19 become available for more people across the United States, questions have been raised about whether institutions like schools and universities should require their students and staff to become vaccinated.

19 Apr 2021

Researchers show how to evaluate waning efficacy of COVID-19 vaccines

Researchers in the United States have demonstrated how to estimate the potentially waning efficacy of vaccines designed to protect against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Apr 2021

Researchers manufacture the SARS-CoV-2 RBD in pichia

Researchers in the United States and India have developed a high-volume, low-cost platform for manufacturing vaccines to protect against different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

19 Apr 2021

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

A recent scientific report from Israel shows how healthcare workers previously infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present with higher Immunoglobulin G (IgG) titers after receiving one dose of Pfizer–BioNTech COVID-19 vaccine in comparison to their fully vaccinated, never-infected counterparts. Conversely, the occurrence of post-vaccination infection does not increase IgG titers.

19 Apr 2021

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.

19 Apr 2021

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Two researchers from the Université Libre de Bruxelles in Belgium, Fabrizio Pucci and Marianne Rooman, recently built a simplified computational model, called SpikePro, to predict the SARS-CoV-2 fitness from the amino acid sequence and structure of the spike protein. This study focuses on the spike protein’s stability and the binding affinity to the host receptor.

19 Apr 2021

Plant-derived compound isorhamnetin may have antiviral potential against SARS-CoV-2

The lack of new or repurposed drugs to treat patients with severe or critical COVID-19 has been one of the biggest hurdles to reducing mortality rates in the ongoing pandemic caused by SARS-CoV-2. A new study describes the potential for the use of the plant molecule isorhamnetin in the management of this virus.

19 Apr 2021

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.

19 Apr 2021

Snag a vaccine appointment, then face the next hurdle: How to get there?

The airport says a lot about Cortez, Colorado: The single-engine planes that fly into its one-room airport seat nine passengers at most.

19 Apr 2021

Study assess prevalence of SARS-CoV-2 in England after third national lockdown

In a new study, the REACT-1 research group offer their findings on the rate of SARS-CoV-2 infection in England after the country went into a third national lockdown. Their findings show a 60% reduction of incidence from their previous round of surveillance.

19 Apr 2021

Research says benefits of continuing immunization of front-line workers in BC with AstraZeneca vaccine far outweigh risks

A recent study by researchers at the University of British Columbia (B.C.) shows that the benefits of continuing the COVID-19 vaccine of front-line workers with the AstraZeneca vaccine outweigh the increased risk of prothrombotic thrombocytopenia.

19 Apr 2021

U.S. vaccinates 131 million Americans against SARS-CoV-2

The country has jabbed over 131 million Americans (39.5% of the Total Population), including over 84 million who have been fully vaccinated (25.4%% of the Total Population).

19 Apr 2021

Obesity, hypertension and smoking linked to lower vaccine-induced antibody production against SARS-CoV-2

In a recent study posted to the medRxiv preprint server, a research group from Italy has demonstrated that the antibody response can be blunted in subjects with certain risk factors shortly after the second dose of mRNA vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Apr 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

Vaccine News and Research

Latest Vaccine News and Research

New machine-learning program accurately identifies COVID-19 conspiracy theories on social media

Despite global efforts, allocation and distribution of COVID-19 vaccines are not equitable

Updated insights for safe COVID-19 vaccination in patients with reported allergic reactions

Sinovac COVID-19 vaccine shows 50% effectiveness in a cohort of Brazilian healthcare workers

Study identifies COVID-19 vaccine inequity in Massachusetts

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

Majority of Americans support COVID-19 vaccine mandates, study finds

Researchers show how to evaluate waning efficacy of COVID-19 vaccines

Researchers manufacture the SARS-CoV-2 RBD in pichia

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Plant-derived compound isorhamnetin may have antiviral potential against SARS-CoV-2

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

Snag a vaccine appointment, then face the next hurdle: How to get there?

Study assess prevalence of SARS-CoV-2 in England after third national lockdown

Research says benefits of continuing immunization of front-line workers in BC with AstraZeneca vaccine far outweigh risks

U.S. vaccinates 131 million Americans against SARS-CoV-2

Obesity, hypertension and smoking linked to lower vaccine-induced antibody production against SARS-CoV-2

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in